Suchergebnisse - "Dall'Olio, Filippo G"

PubPharm (15)

1

Tumour burden and efficacy of immune-checkpoint inhibitors

enthalten in: Nature reviews. Clinical oncology | 2022

von Dall'Olio, F. | Marabelle, A. | Caramella, C. | +5

2

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

enthalten in: Journal for immunotherapy of cancer | 2022

von Cortellini, A. | Ricciuti, B. | Vaz, V. | +32

3

Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC

enthalten in: Therapeutic advances in medical oncology | 2022

von Dall'Olio, F. | Parisi, C. | Marcolin, L. | +12

4

Principles of medical and oncological management of giant masses of the mediastinum : a narrative review

enthalten in: Mediastinum (Hong Kong, China) | 2022

von Conci, N. | Grilli, G. | Dall'Olio, F.

5

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

enthalten in: Clinical lung cancer | 2021

von Dall'Olio, F. | Gelsomino, F. | Conci, N. | +13

6

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Dall'Olio, F. | Calabrò, D. | Conci, N. | +8

7

Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Dall'Olio, F. | Conci, N. | Rossi, G. | +9

8

ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Dall'Olio, F. | Maggio, I. | Massucci, M. | +3

9

Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC : Case Report

enthalten in: Clinical lung cancer | 2020

von Gelsomino, F. | Di Federico, A. | Filippini, D. | +6

10

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

enthalten in: Therapeutic advances in medical oncology | 2020

von Dall'Olio, F. | Abbati, F. | Facchinetti, F. | +7